Jonathan Reynolds MP: speeches

Speeches

• 23 Jun 2025 · UK Modern Industrial Strategy · Hansard source

  More

  I welcome my hon. Friend’s question; he is right that VPAG is significant to the life sciences sector plan and that the industry is looking for resolution on it. The life sciences sector plan will be formally launched by Cabinet colleagues to coincide with the anniversary of the foundation of the NHS. Talks with industry are ongoing and we are trying to find a settlement, which I believe is possible. We should all recognise the economic benefits of the sector for his constituency, which he carefully outlined.

• 1 May 2025 · Topical Questions · Hansard source

  More

  I welcome the progress being made in the hon. Gentleman’s constituency—I thought he was about to invite me there, which is often the case at topical questions, but I sadly did not manage to secure an invitation. I have been absolutely clear: I genuinely wish the inheritance of this Government was a better one in economic terms than the one we received. I genuinely wish the Conservative Government had not left that black hole and that we had not had to make difficult decisions, but life is sometimes about difficult decisions, and Government and business certainly are as well. Without investment in infrastructure, without a serious approach to the fiscal rules, which was absent for much of the last Government, and without investment in the health service, we would struggle. I welcome the success he is talking about; I am always keen to work with him on that.

• 3 Apr 2025 · UK-US Trade and Tariffs · Hansard source

  More

  I thank the hon. Gentleman for his question. He may be aware of the biopharma conference held in the UK yesterday with the top chief executive officers of many of the leading companies in this area. It was attended by myself, the Prime Minister, the Secretary of State for Health and Social Care and the Secretary of State for Science, Innovation and Technology. The hon. Gentleman is right to say that we could see further announcements in this area. There are particular US issues, such as the differential in drug pricing, which has always been a fairly prominent part of trade negotiations. There is an integration and shared aspiration between people in Government, such as myself and the Health Secretary, and recognition of our need to be more forward-leaning, to use more innovation, to look at how we provide that and the relative allocation of resources in our existing health system. We take that very seriously, and we are very much looking at that. There is a lot to do, and it is a difficult situation, but we need more of the success that the hon. Gentleman outlined.

• 3 Apr 2025 · UK-US Trade and Tariffs · Hansard source

  More

  The right hon. Gentleman knows that I do not comment on the detail of talks, but I can tell him that there have been no discussions in relation to the NHS or anything that would concern him in that regard. This is about goods and services and how we recognise each other’s standards. There is nothing relating to the health sector that I have been able to talk about with US counterparts. I hope he finds that reassuring.

• 13 Mar 2025 · Small Business Support · Hansard source

  More

  I thank the hon. Member for her question, and I thank Alison and Kevin for their important work. We already talked about the difficult choices that the Government faced and the unenviable choices that had to be made. Health and social care was a beneficiary of the additional revenue that needed to be raised to meet some of the challenges we face, but we are not casual about the impact of that, and we recognise the pressures that come from that. I would say that I do not agree. Taxes have to apply to every sector, and we cannot carve out certain sectors. However, I appreciate the pressures that she articulates. That is why the rest of the Government’s agenda is set to address all those factors.